Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth

References

• Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology. 2005;10:266–283. doi:10.1111/j.1440-1843.2005.00714.x.
   PubMed Web of Science ®Google Scholar
• Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in great britain from 2002 to 2050. Br J Cancer. 2005;92:587–593. doi:10.1038/sj.bjc.6602307.
   PubMed Web of Science ®Google Scholar
• Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S. ESMO guidelines committee. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis. Treatment Follow-Up Ann Oncol. 2015;26Suppl 5:v31–9. doi:10.1093/annonc/mdv199.
   Web of Science ®Google Scholar
• Margolis RU, Margolis RK. Aggrecan–versican–neurocan family proteoglycans. Methods Enzymol. 1994;245:105–126.
   PubMed Web of Science ®Google Scholar
• Mjaatvedt CH, Yamamura H, Capehart AA, Turner D, Markwald RR. The cspg2 gene, disrupted in the hdf mutant, is required for right cardiac chamber and endocardial cushion formation. Dev Biol. 1998;202:56–66. doi:10.1006/dbio.1998.9001.
   PubMed Web of Science ®Google Scholar
• Dours-Zimmermann MT, Maurer K, Rauch U, Stoffel W, Fässler R, Zimmermann DR. Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the CNS. J Neurosci. 2009;29:7731–7742. doi:10.1523/JNEUROSCI.4158-08.2009.
   PubMed Web of Science ®Google Scholar
• Nara Y, Kato Y, Torii Y, Tsuji Y, Nakagaki S, Isobe H, Nakashima N, Takeuchi J. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem J. 1997;29:21–30.
   PubMedGoogle Scholar
• Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB. Versican/PG-G3 domain promotes tumor growth and angiogenesis. FASEB J. 2004;18:754–756. doi:10.1096/fj.03-0545fje.
   PubMed Web of Science ®Google Scholar
• Hu F, A Dzaye OD, Hahn A, Yu Y, Scavetta RJ, Dittmar G, Kaczmarek AK, Dunning KR, Ricciardelli C, Rinnenthal JL et al. Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. Neuro Oncol. 2015;17:200–210. doi:10.1093/neuonc/nou324.
   PubMed Web of Science ®Google Scholar
• Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457:102–106. doi:10.1038/nature07623.
   PubMed Web of Science ®Google Scholar
• Nandadasa S, Foulcer S, Apte SS. The multiple, complex roles of versican and its proteolytic turnover by ADAMTS proteases during embryogenesis. Matrix Biol. 2014;35:34–41. doi:10.1016/j.matbio.2014.01.005.
   PubMed Web of Science ®Google Scholar
• Sandy JD, Westling J, Kenagy RD, Iruela-Arispe ML, Verscharen C, Rodriguez-Mazaneque JC, Zimmermann DR, Lemire JM, Fischer JW, Wight TN, et al. Versican V1 proteolysis in human aorta in vivo occurs at the glu441–ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem. 2001;276:13372–13378. doi:10.1074/jbc.M009737200.
   PubMed Web of Science ®Google Scholar
• Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S et al. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood. 2016;128:680–685. doi:10.1182/blood-2016-03-705780.
   PubMed Web of Science ®Google Scholar
• Asano K, Nelson CM, Nandadasa S, Aramaki-Hattori N, Lindner DJ, Alban T, Inagaki J, Ohtsuki T, Oohashi T, Apte SS. Stromal versican regulates tumor growth by promoting angiogenesis. Sci Rep. 2017;7:17225.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GT, Kalomenidis I. Malignant pleural effusion: tumor-host interactions unleashed. Am J Respir Crit Care Med. 2012;186:487–492. doi:10.1164/rccm.201203-0465PP.
   PubMed Web of Science ®Google Scholar
• Li MO, Rudensky AY. T cell receptor signalling in the control of regulatory T cell differentiation and function. Nat Rev Immunol. 2016;16:220–233. doi:10.1038/nri.2016.26.
   PubMed Web of Science ®Google Scholar
• Van Schil PE, Opitz I, Weder W, De Laet C, Domen A, Lauwers P, Hendriks JM, Van Meerbeeck JP. Multimodal management of malignant pleural mesothelioma: where are we today? Eur Respir J. 2014;44:754–764. doi:10.1183/09031936.00207213.
   PubMed Web of Science ®Google Scholar
• Du WW, Fang L, Yang X, Sheng W, Yang BL, Seth A, Zhang Y, Yang BB, Yee AJ. The role of versican in modulating breast cancer cell self-renewal. Mol Cancer Res. 2013;11:443–455. doi:10.1158/1541-7786.MCR-12-0461.
   PubMed Web of Science ®Google Scholar
• Kunisada M, Yogianti F, Sakumi K, Ono R, Nakabeppu Y, Nishigori C. Increased expression of versican in the inflammatory response to UVB- and reactive oxygen species-induced skin tumorigenesis. Am J Pathol. 2011;179:3056–3065. doi:10.1016/j.ajpath.2011.08.042.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49–61. doi:10.1016/j.immuni.2014.06.010.
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. doi:10.1016/j.cell.2006.02.015.
   PubMed Web of Science ®Google Scholar
• Wight TN, Kang I, Merrilees MJ. Versican and the control of inflammation. Matrix Biol. 2014;35:152–161. doi:10.1016/j.matbio.2014.01.015.
   PubMed Web of Science ®Google Scholar
• Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet. 2005;366:397–408. doi:10.1016/S0140-6736(05)67025-0.
   PubMed Web of Science ®Google Scholar
• Giannou AD, Marazioti A, Spella M, Kanellakis NI, Apostolopoulou H, Psallidas I, Prijovich ZM, Vreka M, Zazara DE, Lilis I et al. Mast cells mediate malignant pleural effusion formation. J Clin Invest. 2015;125:2317–2334. doi:10.1172/JCI79840.
   PubMed Web of Science ®Google Scholar
• Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer. 2017;17:475–488. doi:10.1038/nrc.2017.42.
   PubMed Web of Science ®Google Scholar
• Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18:623–630. doi:10.1016/S1470-2045(17)30169-9.
   PubMed Web of Science ®Google Scholar
• Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, Robinson BW, Nelson DJ. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2003;171:5051–5063.
   PubMed Web of Science ®Google Scholar
• Bielefeldt-Ohmann H, Marzo AL, Himbeck RP, Jarnicki AG, Robinson BW, Fitzpatrick DR. Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother. 1995;40:241–250.
   PubMed Web of Science ®Google Scholar
• Zhang X, Goncalves R, Mosser DM. The isolation and characterization of murine macrophages. Curr Protoc Immunol. 2008;83:14. doi:10.1002/0471142735.im1401s83. PMID: 19016445
   Google Scholar
• Van Beijnum JR, Rousch M, Castermans K, van der Linden E, Griffioen AW. Isolation of endothelial cells from fresh tissues. Nat Protoc. 2008;3:1085–1091.
   PubMed Web of Science ®Google Scholar
• Magkouta S, Pappas A, Moschos C, Vazakidou ME, Psarra K, Kalomenidis I. Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion. Oncotarget. 2016;7:20249–20259. doi:10.18632/oncotarget.7912.
   PubMedGoogle Scholar
• Vazakidou ME, Magkouta S, Moschos C, Psallidas I, Pappas A, Psarra K, Kalomenidis I. Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo. Respirology. 2015;20:1263–1271. doi:10.1111/resp.12604.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GT, Psallidas I, Moustaki A, Moschos C, Kollintza A, Karabela S, Porfyridis I, Vassiliou S, Karatza M, Zhou Z et al. A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion. J Natl Cancer Inst. 2008;100:1464–1476. doi:10.1093/jnci/djn325.
   PubMed Web of Science ®Google Scholar
• Psallidas I, Stathopoulos GT, Maniatis NA, Magkouta S, Moschos C, Karabela SP, Kollintza A, Simoes DC, Kardara M, Vassiliou S et al. Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion. Oncogene. 2013;32:528–535. doi:10.1038/onc.2012.57.
   PubMed Web of Science ®Google Scholar